Drug Safety
This page lists 265 references in the Main Healthy Skepticism Library relevant to Drug Safety.
Click on the HSL (Health Skepticism Library) number for more details which may include an abstract or full text.
HSL8532
Houston Business Journal.
Bayer reaches settlement over drug disclosure
Houston Business Journal 2007 Jan 23
http://houston.bizjournals.com/houston/stories/2007/01/22/daily29.html
HSL6877
Tartaglia LA.
Complementary new approaches enable repositioning of failed drug candidates.
Expert Opin Investig Drugs 2006 Nov 01;15(11):1295-8
http://www.expertopin.com/doi/abs/10.1517/13543784.15.11.1295
HSL6939
Lee YH, Ji JD, Song GG.
Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk.
Rheumatol Int. 2006 Oct 19
HSL6965
Hauptman PJ, Schnitzler MA, Swindle J, Burroughs TE.
Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure.
JAMA. 2006 Oct 18;296(15):1877-84
HSL6901
Carrie AG, Grymonpre RE, Blandford AA.
Impact of Residence on Prevalence and Intensity of Prescription Drug Use Among Older Adults (November).
Ann Pharmacother 2006 Oct 10
http://www.theannals.com/cgi/reprint/aph.1H338v1
HSL6819
Dowden JS.
Injunction impedes independent information
Australian Prescriber 2006 Oct 1;29(5):120
http://www.australianprescriber.com/upload/pdf/articles/828.pdf
HSL6937
Jick H, Kaye JA, Russmann S, Jick SS.
Nonsteroidal antiinflammatory drugs and acute myocardial infarction in patients with no major risk factors
Pharmacotherapy. 2006 Oct 1;26(10):1379-87
HSL6972
Schussel K, Schulz M.
Prescribing of COX-2 inhibitors in Germany after safety warnings and market withdrawals
Pharmazie 2006 Oct 1;61(10):878-86
HSL6879
Jensen JW.
[Be careful on the Internet].
Ugeskr Laeger 2006 Sep 18;168(38):3189
HSL6769
Benjamin DK Jr, Smith PB, Murphy MD, Roberts R, Mathis L, Avant D, Califf RM, Li JS.
Peer-reviewed publication of clinical trials completed for pediatric exclusivity.
JAMA 2006 Sep 13;296(10):1266-73
http://jama.ama-assn.org/cgi/content/full/296/10/1266
HSL6740
Charatan F.
US judge dismisses 50m dollars damages in Vioxx lawsuit.
BMJ 2006 Sep 9;333(7567):516
http://bmj.bmjjournals.com/cgi/content/full/333/7567/516-c
HSL6664
Munoz C, Hilgenberg C.
Ethnopharmacology: understanding how ethnicity can affect drug response is essential to providing culturally competent care.
Holist Nurs Pract 2006 Sep-Oct 01;20(5):227-34
Link to source with long URL
HSL6538
Cuzzolin L, Atzei A, Fanos V.
Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety.
Expert Opin Drug Saf 2006 Sep 01;5(5):703-18
http://www.expertopin.com/doi/abs/10.1517/14740338.5.5.703
HSL6686
Sleeping pills: are they worth the risk?
Consum Rep 2006 Sep 01;71(9):48-9
HSL6800
Akunyili D.
Dora Akunyili: battling against counterfeit drugs. Interview by Marilynn Larkin.
Lancet Infect Dis 2006 Sep 01;6(9):554-5
http://linkinghub.elsevier.com/retrieve/pii/S1473-3099(06)70575-8
HSL6830
Stern RS.
Topical calcineurin inhibitors labeling: putting the 'box' in perspective.
Arch Dermatol 2006 Sep 01;142(9):1233-5
http://archderm.ama-assn.org/cgi/content/full/142/9/1233
HSL6317
Goodyear M.
Further lessons from the TGN1412 tragedy
BMJ 2006 Aug 5;333(7562):270-271
http://bmj.bmjjournals.com/cgi/content/short/333/7562/270?etoc%3e
HSL6749
Sipkoff M.
Off-label use often presents conundrum for health plans.
Manag Care 2006 Aug 01;15(8):15-6
HSL6110
Smith R.
Lapses at the New England Journal of Medicine
Journal of the royal society of medicine 2006 Aug 1;99
http://www.rsmpress.co.uk/0607JRSMSmith.pdf
HSL6318
Kmietowicz Z.
Rules for drug trials should be tightened, say experts
http://bmj.bmjjournals.com/cgi/content/short/333/7562/276-a?etoc%3e 2006 Aug 01;333(7562):276
http://bmj.bmjjournals.com/cgi/content/short/333/7562/276-a?etoc%3e
HSL6549
Cromer BA, Scholes D, Berenson A, Cundy T, Clark MK, Kaunitz AM; Society for Adolescent Medicine.
Depot medroxyprogesterone acetate and bone mineral density in adolescents--the Black Box Warning: a Position Paper of the Society for Adolescent Medicine.
J Adolesc Health 2006 Aug 01;39(2):296-301
http://linkinghub.elsevier.com/retrieve/pii/S1054-139X(06)00098-X
HSL6730
Olfson M, Marcus SC, Shaffer D.
Antidepressant drug therapy and suicide in severely depressed children and adults: A case-control study.
Arch Gen Psychiatry 2006 Aug 01;63(8):865-72
http://archpsyc.ama-assn.org/cgi/content/full/63/8/865
HSL6751
Ornes L, Hendrix TJ.
Prescription drug re-importation: a balanced look.
J Gerontol Nurs 2006 Aug 01;32(8):15-9
HSL6752
Kripalani S, Henderson LE, Chiu EY, Robertson R, Kolm P, Jacobson TA.
Predictors of medication self-management skill in a low-literacy population.
J Gen Intern Med 2006 Aug 01;21(8):852-6
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1525-1497.2006.00536.x
HSL6753
Davis TC, Wolf MS, Bass PF 3rd, Middlebrooks M, Kennen E, Baker DW, Bennett CL, Durazo-Arvizu R, Bocchini A, Savory S, Parker RM.
Low literacy impairs comprehension of prescription drug warning labels.
J Gen Intern Med 2006 Aug 01;21(8):847-51
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1525-1497.2006.00529.x
HSL6833
Klein DF.
FDA post-marketing safety decisions.
J Clin Psychiatry 2006 Aug 01;67(8):1305-6
http://article.psychiatrist.com/?ContentType=START&ID=10002685
HSL6202
Roehr B.
Institute of Medicine report strives to reduce medication errors
BMJ 2006 Jul 29;333(7561):220
http://bmj.bmjjournals.com/cgi/content/short/333/7561/220-f?etoc%3e
HSL6775
Shuttleworth A.
Adverse drug reactions.
Nurs Times 2006 Jul 25-31;102(30):58
HSL6142
Laffan G.
Vitamins promoter goes on trial for fraud
BMJ 2006 Jul 22;333(7560):166
http://bmj.bmjjournals.com/cgi/content/short/333/7560/166-b?etoc%3e
HSL6123
Dobson R.
NEJM “failed its readers” by delay in publishing its concerns about VIGOR trial
BMJ 2006 Jul 15;333(7559):116
http://bmj.bmjjournals.com/cgi/content/short/333/7559/116-f?etoc
HSL6124
Ferner RE, Aronson JK.
Drugs: Communicating information about drug safety
BMJ 2006 Jul 15;333(7559):143-145
http://bmj.bmjjournals.com/cgi/content/short/333/7559/143?etoc
HSL5994
Healy D.
Did regulators fail over selective serotonin reuptake inhibitors?
BMJ 2006 Jul 8;333(7558):92-95
http://bmj.bmjjournals.com/cgi/content/short/333/7558/92?etoc
HSL6125
Godlee F.
Can we tame the monster?
BMJ 2006 Jul 8;333(7558)
http://bmj.bmjjournals.com/cgi/content/full/333/7558/0-f
HSL6846
McHenry L.
Ethical issues in psychopharmacology.
J Med Ethics 2006 Jul 01;32(7):405-10
http://jme.bmjjournals.com/cgi/content/full/32/7/405
HSL5956
Cassels A.
Women’s health and the Flat Earth Society
Common Ground 2006 Jul 1
http://www.commonground.ca/iss/0607180/cg180_cassels.shtml
HSL6704
Ansani N, Sirio C, Smitherman T, Fedutes-Henderson B, Skledar S, Weber RJ, Zgheib N, Branch R.
Designing a strategy to promote safe, innovative off-label use of medications.
Am J Med Qual 2006 Jul-Aug 01;21(4):255-61
http://ajm.sagepub.com/cgi/reprint/21/4/255
HSL6705
Ansani N, Branch R, Fedutes-Henderson B, Smitherman T, Weber RJ, Skledar S, Zgheib N, Sirio C.
United States medical practice summary: innovative off-label medication use.
Am J Med Qual 2006 Jul-Aug 01;21(4):246-54
http://ajm.sagepub.com/cgi/reprint/21/4/246
HSL6803
Abraham IL, MacDonald KM.
Postapproval drug safety.
Health Aff (Millwood) 2006 Jul-Aug 01;25(4):1186-7
http://content.healthaffairs.org/cgi/content/full/25/4/1186-b
HSL6805
Kesselheim AS, Fischer MA, Avorn J.
The rise and fall of Natrecor for congestive heart failure: implications for drug policy.
Health Aff (Millwood) 2006 Jul-Aug 01;25(4):1095-102
http://content.healthaffairs.org/cgi/content/full/25/4/1095
HSL6885
Dubey AK, Palaian S, Shankar PR, Mishra P, Prabhu M, Bhandari RB, Chhetri AK.
Introduction to medication errors and the error prevention initiatives in a teaching hospital in Western Nepal.
Pak J Pharm Sci 2006 Jul 01;19(3):244-51
HSL5808
Hagan P.
Four in five asthma deaths may be due to long acting beta agonists.
BMJ 2006 Jun 24;332(7556):1467
http://bmj.bmjjournals.com/cgi/content/extract/332/7556/1467-a
HSL6754
Piguet V, Allaz AF.
[Internet analgesic prescriptions for chronic pain].
Rev Med Suisse 2006 Jun 21;2(71):1619-20
HSL5722
Eaton L.
European agency approves use of fluoxetine for children and teens.
BMJ 2006 Jun 17;332(7555):1407
http://bmj.bmjjournals.com/cgi/content/short/332/7555/1407-a?etoc
HSL5729
Saperia J, Ashby D, Gunnell D.
Suicidal behaviour and SSRIs: updated meta-analysis.
BMJ 2006 Jun 17;332(7555):1453
http://bmj.bmjjournals.com/cgi/content/short/332/7555/1453-a?etoc
HSL5768
Millson DS.
Ethnic differences in risks of adverse reactions: is personalised drug treatment better with pharmacokinetic modelling?
BMJ 2006 Jun 10;332(7554):1393
http://bmj.bmjjournals.com/cgi/content/short/332/7554/1393?etoc
HSL5770
Couper MR, Pal SN, Rago L, Sawyer J.
WHO perspective on preventing avoidable harm from medicines.
BMJ 2006 Jun 10;332(7554):1393-4
http://bmj.bmjjournals.com/cgi/content/short/332/7554/1393-b?etoc
HSL5992
Dobson R.
Diethylstilbestrol increases risk of breast cancer death
BMJ 2006 Jun 8;333(7558):64
http://bmj.bmjjournals.com/cgi/content/short/333/7558/64-d?etoc
HSL6213
Strandberg K.
[Sweden can contribute to safer drug assessment]
Lakartidningen 2006 Jun 8-13;103(23):1853-5
HSL5531
Emslie GJ, Wagner KD, Kutcher S, Krulewicz S, Fong R, Carpenter DJ, Lipschitz A, Machin A, Wilkinson C.
Paroxetine Treatment in Children and Adolescents With Major Depressive Disorder: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial.
J Am Acad Child Adolesc Psychiatry 2006 Jun 01;45(6):709-719
Link to source with long URL
HSL5819
Krautkramer CJ.
Neurontin and off-label marketing
Virtual Mentor: Ethics Journal of the American Medical Association 2006 Jun 1;8(6):397-402
HSL6383
Livesey JE, Chiew YF.
Antimicrobial drug utilisation in Dunedin Hospital, New Zealand, and its association with antimicrobial resistance.
Pathology 2006 Jun 01;38(3):245-8
Link to source with long URL
HSL6617
Blockman M.
Selective serotonin reuptake inhibitors in children with major depression.
S Afr Med J 2006 Jun 01;96(6):476-7
Link to source with long URL
HSL6711
Katz A.
Testosterone for women: necessary or noxious?
AWHONN Lifelines 2006 Jun-Jul 01;10(3):208-9
HSL6987
Balit CR, Lynch AM, Gilmore SP, Murray L, Isbister GK.
Lignocaine and chlorhexidine toxicity in children resulting from mouth paint ingestion: a bottling problem.
J Paediatr Child Health 2006 Jun 01;42(6):350-3
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1440-1754.2006.00871.x
HSL6988
Eiland LS, Knight P.
Evaluating the off-label use of medications in children.
Am J Health Syst Pharm 2006 Jun 1;63(11):1062-5
http://www.ajhp.org/cgi/content/full/63/11/1062
HSL6989
Wolf MS, Davis TC, Tilson HH, Bass PF 3rd, Parker RM.
Misunderstanding of prescription drug warning labels among patients with low literacy.
Am J Health Syst Pharm 2006 Jun 1;63(11):1048-55
http://www.ajhp.org/cgi/content/full/63/11/1048
HSL5736
Lenzer J.
Secret report surfaces showing that Pfizer was at fault in Nigerian drug tests.
BMJ 2006 May 27;332(7552):1233
http://bmj.bmjjournals.com/cgi/content/full/332/7552/1233-a
HSL5742
Wadman M.
How does a painkiller harm the heart?
Nature 2006 May 18;441(7091):262
http://www.nature.com/news/2006/060515/full/441264a.html
HSL5576
Hass DJ, Lewis JD.
Quality of manufacturer provided information on safety and efficacy claims for dietary supplements for colonic health.
Pharmacoepidemiol Drug Saf 2006 May 15
Link to source with long URL
HSL5481
Hitchen L.
Adverse drug reactions result in 250,000 UK admissions a year.
BMJ 2006 May 13;332(7550):1109
http://bmj.bmjjournals.com/cgi/content/full/332/7550/1109
HSL5484
Tanne JH.
Rofecoxib may cause heart attacks in first weeks of use.
BMJ 2006 May 13;332(7550):1114
http://bmj.com/cgi/content/short/332/7550/1114?etoc
HSL5621
Mayor S.
Cancer charity is to 'borrow' candidate drugs shelved by companies.
BMJ 2006 May 13;332(7550):1112
http://bmj.bmjjournals.com/cgi/content/full/332/7550/1112
HSL5666
Silversides A.
Former director general: Health Canada needs broader drug safety powers.
CMAJ 2006 May 9;174(10):1395-6
http://www.cmaj.ca/cgi/content/full/174/10/1395
HSL5563
Wood AJ, Darbyshire J.
Injury to research volunteers--the clinical-research nightmare.
N Engl J Med 2006 May 4;354(18):1869-71
http://content.nejm.org/cgi/content/extract/354/18/1869
HSL5614
[No authors listed].
Second FDA panel advises on stimulants.
Child Health Alert 2006 May 01;24:4
HSL6224
Collis MC.
Integrative pharmacology and drug discovery--is the tide finally turning?
Nat Rev Drug Discov 2006 May 01;5(5):377-9
Link to source with long URL
HSL6758
Bignone IM.
[Issues regarding the legal regulation of drugs in Argentina].
Vertex 2006 May-Jun 01;17(67):220-3
HSL5496
Biron P, Mintzes B, Lexchin J.
Questions about Adderall XR.
CMAJ 2006 Apr 25;174(9):1303-4
http://www.cmaj.ca/cgi/content/full/174/9/1303-a
HSL5682
Tanne JH.
Court awards claimant 13.5m dollars in rofecoxib lawsuit
BMJ. 2006 Apr 22;332(7547):927
http://bmj.bmjjournals.com/cgi/content/full/332/7547/927-a
HSL5565
Benko LB.
Drug lawsuits building. Merck, Pfizer facing charges of misrepresentation.
Mod Healthc 2006 Apr 10;36(15):16
HSL5683
Abbasi K.
Unconvincing Pfizer and uncertain crucifixions.
J R Soc Med 2006 Apr 01;99(4):163
http://www.jrsm.org/cgi/content/full/99/4/163
HSL5962
Kline AD.
On complicity theory.
Sci Eng Ethics 2006 Apr 01;12(2):257-64
HSL6092
Klein , Donald F.
The flawed basis for FDA post-marketing safety decisions: The example of anti-depressants and children
Neuropsychopharmacology 2006 Apr 01;31(4):689-699
http://www.nature.com/npp/
HSL6618
Ghebrehiwet T.
Counterfeits kill!
Imprint. 2006 Apr-May 01;53(3):40-4
HSL6763
Di Paolo ER, Stoetter H, Cotting J, Frey P, Gehri M, Beck-Popovic M, Tolsa JF, Fanconi S, Pannatier A.
Unlicensed and off-label drug use in a Swiss paediatric university hospital.
Swiss Med Wkly 2006 Apr 1;136(13-14):218-22
http://www.smw.ch/dfe/set_archiv.asp?target=2006/13/smw-11275
HSL6990
Hackford R.
With the recent Food and Drug Administration (FDA) Advisory Committee's recommendation to put a black box warning on stimulants, the government has joined the media in raising alarm about the medical treatment of attention-deficit disorder.
J Dev Behav Pediatr 2006 Apr 01;27(2):179
Link to source with long URL
HSL5562
Debate over warnings for ADHD stimulants.
Child Health Alert 2006 Apr;24(1)
HSL5684
Wadman M.
London's disastrous drug trial has serious side effects for research.
Nature 2006 Mar 23;440(7083):388-9
http://www.nature.com/doifinder/10.1038/440388a
HSL4355
Lenzer J.
Antidepressants double suicidality in children, says FDA
BMJ 2006 Mar 18;2006;332:626(doi:10.1136/bmj.332.)
http://bmj.bmjjournals.com/cgi/content/extract/332/7542/626-c
HSL5376
Make or break time in Vioxx drama.
Nature 2006 Mar 16;440(7082):277
Link to source with long URL
HSL6849
Ridley DB, Kramer JM, Tilson HH, Grabowski HG, Schulman KA.
Spending on postapproval drug safety.
Health Aff (Millwood) 2006 Mar-Apr 01;25(2):429-36
http://content.healthaffairs.org/cgi/content/full/25/2/429
HSL5672
Pickering TG.
Class effects and labeling of antihypertensive drugs.
J Clin Hypertens (Greenwich) 2006 Mar 01;8(3):215-20
Link to source with long URL
HSL6106
Kolch M, Lippert HD, Fegert JM.
[The effects of the 12th and 14th amendments to the AMG (Medical Preparations Act) on paediatric pharmaceutical research--a survey of the new regulations].
Z Kinder Jugendpsychiatr Psychother 2006 Mar 01;34(2):117-26
HSL6228
Winterstein AG, Hartzema AG, Johns TE, De Leon JM, McDonald K, Henshaw Z, Pannell R.
Medication safety infrastructure in critical-access hospitals in Florida.
Am J Health Syst Pharm 2006 Mar 1;63(5):442-50
http://www.ajhp.org/cgi/content/full/63/5/442
HSL6229
Traynor K.
FDA resurrects, finalizes labeling rule.
Am J Health Syst Pharm 2006 Mar 1;63(5):398,
http://www.ajhp.org/cgi/content/full/63/5/398
HSL5604
Wadman M.
One year after launch, drug safety board is dubbed a failure.
Nat Med 2006 Mar;12(3):258
http://www.nature.com/doifinder/10.1038/nm0306-258b
HSL5286
Sauter B.
Growth hormone for 'antiaging'.
JAMA 2006 Feb 22;295(8):889
http://jama.ama-assn.org/cgi/content/full/295/8/889-a
HSL5360
Sandstrom H.
[More than 1 out of 100 will have myocardial infarction and stroke because of enalapril--effect of drug package inserts?]
Lakartidningen 2006 Feb 22-28;103(8):564,
HSL5692
Lexchin J .
Withdrawals of drugs for safety reasons: How do regulators decide if they are too unsafe?
Reaction Bulletin 2006 Feb 1;236
HSL5340
Autret-Leca E, Bensouda-Grimaldi L, Le Guellec C, Jonville-Bera AP.
[Prescriptions and children].
Arch Pediatr 2006 Feb;13(2):181-5
Link to source with long URL
HSL5364
Wadman M.
Earlier drug tests on people could be unsafe, critics warn.
Nat Med 2006 Feb;12(2):153
Link to source with long URL
HSL5378
Counterfeit medicines: the silent epidemic.
Indian J Med Sci 2006 Feb;60(2):82-3
HSL5383
McEleney P.
A case of mislabelling.
J Perioper Pract 2006 Feb;16(2):63
HSL5433
MacLennan AH, Sturdee DW.
The 'bioidentical/bioequivalent' hormone scam.
Climacteric 2006 Feb;9(1):1-3
HSL5567
Roggla G, Moser B.
Re: Bioethics, the Surviving Sepsis Campaign, and the industry.
Wien Klin Wochenschr 2006 Feb;118(1-2):65
HSL5568
Ricevuti G, Gasparetto C.
Re: Bioethics, the Surviving Sepsis Campaign, and the industry.
Wien Klin Wochenschr 2006 Feb;118(1-2):64-5
HSL5569
Mackenzie AF.
Re: Bioethics, the Surviving Sepsis Campaign, and the industry.
Wien Klin Wochenschr 2006 Feb;118(1-2):64
HSL5570
Malliani A.
Re: Bioethics, the Surviving Sepsis Campaign, and the industry.
Wien Klin Wochenschr 2006 Feb;118(1-2):63-4
HSL5572
Bion J, Vincent JL, Angood P.
Bioethics, the Surviving Sepsis Campaign and the industry.
Wien Klin Wochenschr 2006 Feb;118(1-2):63
HSL5388
Cina J, Fanikos J, Mitton P, McCrea M, Churchill W.
Medication errors in a pharmacy-based bar-code-repackaging center.
Am J Health Syst Pharm 2006 Jan 15;63(2):165-8
http://www.ajhp.org/cgi/content/full/63/2/165
HSL5686
Skiba M.
Strategies for identifying and minimizing medication errors in health care settings.
Health Care Manag (Frederick) 2006 Jan-Mar 01;25(1):70-7
Link to source with long URL
HSL5689
Kondrak G, Dorr B.
Automatic identification of confusable drug names.
Artif Intell Med 2006 Jan 01;36(1):29-42
http://linkinghub.elsevier.com/retrieve/pii/S0933-3657(05)00100-4
HSL6208
Chur-Hansen A, Zion D.
'Let's fix the chemical imbalance first, and then we can work on the problems second': an exploration of ethical implications of prescribing an SSRI for 'depression'.
Monash Bioeth Rev 2006 Jan 01;25(1):15-30
HSL5239
Murphy S, Roberts R.
'Black box' 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk.
J Allergy Clin Immunol 2006 Jan;117(1):34-9
http://linkinghub.elsevier.com/retrieve/pii/S0091-6749(05)02325-0
HSL5241
Szefler SJ, Whelan GJ, Leung DY.
'Black box' warning: wake-up call or overreaction?
J Allergy Clin Immunol 2006 Jan;117(1):26-9
http://linkinghub.elsevier.com/retrieve/pii/S0091-6749(05)02509-1
HSL5308
Prescription for trouble: common drugs, hidden dangers Tens of people are at risk.
Consum Rep 2006 Jan;71(1):34-9
HSL5319
Warning on unapproved alternative hormone therapies.
FDA Consum 2006 Jan-Feb;40(1):2
Link to source with long URL
HSL5520
Busfield J.
Pills, Power, People: Sociological Understandings of the Pharmaceutical Industry
2006;40(2):297-314
http://soc.sagepub.com/cgi/content/abstract/40/2/297?etoc
HSL6093
Breggin PR
Court filing makes public my previously suppressed analysis of Paxil's effects.
Ethical Human Psychology and Psychiatry 2006 Spr;8(1):77-84
http://www.springerpub.com/
HSL6499
Vuorenkoski L.
[The case of rofecoxib(Vioxx)-what do we learn from this case].
Duodecim 2006;122(4):385-6
HSL6569
Kuczkowski KM.
Drug mislabeling erros in (obsteric) anaesthesia.
Acta Anaesthesiol Belg 2006;57(1):57
HSL6761
FDA electronic drug labels to improve patient safety.
J Pain Palliat Care Pharmacother 2006;20(2):96-7
HSL6791
Loucks MK.
Pros and cons of off-label promotion investigations and prosecutions.
Food Drug Law J 2006;61(3):577-83
HSL6792
Vernon W.
The Canadian perspective: trends in drug and medical device class actions in Canada.
Food Drug Law J 2006;61(3):569-76
HSL6822
Herdeiro MT, Figueiras A, Polonia J, Gestal-Otero JJ.
Influence of pharmacists' attitudes on adverse drug reaction reporting: a case-control study in Portugal.
Drug Saf 2006;29(4):331-40
HSL5650
Thygeson M.
Five fixes to improve drug safety. Ideas for how to prevent another Vioxx debacle
Minn Med. 2005 Dec 01;88(12):36-7
HSL5220
Tuohy N, Paparella S.
Look-alike and sound-alike drugs: errors just waiting to happen.
J Emerg Nurs 2005 Dec;31(6):569-71
http://linkinghub.elsevier.com/retrieve/pii/S0099-1767(05)00437-X
HSL5333
Mazor KM, Andrade SE, Auger J, Fish L, Gurwitz JH.
Communicating safety information to physicians: an examination of dear doctor letters.
Pharmacoepidemiol Drug Saf 2005 Dec;14(12):869-75
Link to source with long URL
HSL5654
Mathews AW.
An FDA reviewer battles the drug his boss approved: private letter gets Dr. Misbin pulled from diabetes case but he pursues it anyway.
Wall St J (East Ed) 2005 Oct 26;A1
HSL5253
Krieger N, Lowy I, Aronowitz R, Bigby J, Dickersin K, Garner E, Gaudilliere JP, Hinestrosa C, Hubbard R, Johnson PA, Missmer SA, Norsigian J, Pearson C, Rosenberg CE, Rosenberg L, Rosenkrantz BG, Seaman B, Sonnenschein C, Soto AM, Thornton J, Weisz G.
Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives.
J Epidemiol Community Health 2005 Sep 01;59(9):740-8
http://jech.bmjjournals.com/cgi/content/full/59/9/740
HSL5657
Filimonov D, Poroikov V.
Why relevant chemical information cannot be exchanged without disclosing structures.
J Comput Aided Mol Des 2005 Sep-Oct 01;19(9-10):705-13
Link to source with long URL
HSL2624
Smith A.
Jury: Merck negligent
CNN/Money 2005 Aug 19
http://money.cnn.com/2005/08/19/news/fortune500/vioxx/index.htm
HSL2625
Health Canada launches MedEffect on its new website
Health Canada 2005 Aug 18
http://www.hc-sc.gc.ca/dhp-mps/medeff/index_e.html
HSL6016
Mansfield PR, Jureidini JN.
Re: Fluoxetine for depressed adolescents: harms likely to exceed benefits
BMJ 2005 Aug 16;330
http://bmj.bmjjournals.com/cgi/eletters/330/7493/730-b
HSL6514
Keisler BD, Hosey RG.
Ergogenic aids: an update on ephedra.
Curr Sports Med Rep 2005 Aug 01;4(4):231-5
HSL2431
Fuller J, Ashar BS, Carey-Corrado J.
Trocar-associated injuries and fatalities: An analysis of 1399 reports to the FDA.
J Minim Invasive Gynecol 2005 Aug;12(4):302-307
Link to source with long URL
HSL6408
Why PLoS sponsored a roundtable of medical whistleblowers.
PLoS Med 2005 Jul 01;2(7):e208
Link to source with long URL
HSL2247
Safety and Efficacy of SSRIs in Children and Adolescents
American Medical Association 2005 Jun 29
http://www.ama-assn.org/ama/pub/category/print/15186.html
HSL1915
Jackson L.
A marketing breakthrough
Mediawatch ABC Online 2005 Jun 13
http://www.abc.net.au/mediawatch/transcripts/s1390967.htm
HSL1908
Don't use growth hormone sold over web: Health Canada
CBC News 2005 Jun 7
HSL1905
Levin M.
Firm Removed Mercury From Nasal Spray, Not Infant Shots: Wyeth used thimerosal in vaccines for years after it did away with the chemical in Dristan.
The LA Times 2005 Jun 4
HSL1910
Anderson C.
Court: Pharmacists Can Be Liable for Drugs
Associated Press 2005 Jun 3
HSL4237
Diller L.
Antidepressants and children's depression.
Am J Psychiatry 2005 Jun 01;162(6):1226-7
http://ajp.psychiatryonline.org/cgi/content/full/162/6/1226-a
HSL5892
Nebeker JR, Hoffman JM, Weir CR, Bennett CL, Hurdle JF.
High rates of adverse drug events in a highly computerized hospital.
Arch Intern Med 2005 May 23;165(10):1111-6
http://archinte.ama-assn.org/cgi/content/full/165/10/1111
HSL1867
Carey B.
F.D.A. Considers Implant Device for Depression
The New York Times 2005 May 21
HSL1866
Wilde-mathews A.
Brain Neurostimulation Shown to Relieve Severe Depression for Some: Ruling on Medical Device Examined
THE WALL STREET JOURNAL 2005 May 19
HSL1861
Henderson D.
Acne drug reduces teen depression: Study looks at link between Accutane, suicidal behavior
The Boston Globe 2005 May 17
HSL1862
Saul S.
The Marketing and Success of Natrecor
The New York Times 2005 May 17
HSL1832
Common drugs raise heart threat
BBC News 2005 May 11
http://news.bbc.co.uk/go/pr/fr/-/1/hi/health/4535697.stm
HSL1834
Silverman E.
Biz Buzz: Actress's on-screen personalities collide at conference
New Jersey Star Ledger 2005 May 11
HSL1852
Edelman S.
CONTRA-DECEPTION
The New York Post 2005 May 9
HSL1774
Kaufman M.
Merck CEO Resigns as Drug Probe Continues
The Washington Post 2005 May 6
HSL1771
Solomon J.
Researchers Tested AIDS Drugs on Children
LA Times 2005 May 4
HSL1778
Harris G.
Petition Seeks Warning on Anticancer Medication
The New York Times 2005 May 4
HSL1838
Tansey B.
Why doctors prescribe off label
San Francisco Chronicle 2005 May 1
HSL4219
Hamrin V, Scahill L.
Selective serotonin reuptake inhibitors for children and adolescents with major depression: current controversies and recommendations.
Issues Ment Health Nurs 2005 May 01;26(4):433-50
HSL4233
Allen TS Jr, Henderson JH Jr.
Merck VIOXX "warning" is questioned.
Tex Med 2005 May 01;101(5):5-6
HSL5449
Kaltwasser JP, Behrens F.
Leflunomide: long-term clinical experience and new uses.
Expert Opin Pharmacother 2005 May 01;6(5):787-801
Link to source with long URL
HSL5459
Litten RZ, Fertig J, Mattson M, Egli M.
Development of medications for alcohol use disorders: recent advances and ongoing challenges.
Expert Opin Emerg Drugs 2005 May 01;10(2):323-43
http://www.expertopin.com/doi/abs/10.1517/14728214.10.2.323
HSL1855
Berenson A.
Evidence in Vioxx Suits Shows Intervention by Merck Officials
The New York Times 2005 Apr 24
HSL5512
Cockburn R, Newton PN, Agyarko EK, Akunyili D, White NJ.
The global threat of counterfeit drugs: why industry and governments must communicate the dangers.
PLoS Med 2005 Apr 01;2(4):e100
Link to source with long URL
HSL5685
Manchester A.
Counterfeit medicines kill.
Nurs N Z 2005 Apr 01;11(3):10
HSL1830
Burton R.
How Merck stacked the Vioxx deck
Salon.com 2005 Mar 31
HSL1219
Lexchin J.
Drug withdrawals from the Canadian market for safety reasons, 1963-2004.
CMAJ 2005 Mar 15;172(6):765-7
http://www.cmaj.ca/cgi/content/full/172/6/765
HSL5885
Koppel R, Metlay JP, Cohen A, Abaluck B, Localio AR, Kimmel SE, Strom BL.
Role of computerized physician order entry systems in facilitating medication errors.
JAMA 2005 Mar 9;293(10):1197-203
http://jama.ama-assn.org/cgi/content/full/293/10/1197
HSL1839
Tansey B.
Hard sell: How Marketing Drives the Pharmaceutical Industry: What FDA approval means: Agency weighs benefits, risks before drugs get to market
San Francisco Chronicle 2005 Mar 3
HSL669
Monarin G-L.
Proceed with caution
Med Ad News 2005 Mar;24(3)
http://www.pharmalive.com/magazines/medad/view.cfm?articleID=1872
HSL4049
'Black box' warning added to contraceptive injection.
FDA Consum 2005 Mar-Apr 01;39(2):3
http://www.fda.gov/fdac/departs/2005/205_upd.html
HSL4050
New warning about ADHD drug.
FDA Consum 2005 Mar-Apr 01;39(2):3
http://www.fda.gov/fdac/departs/2005/205_upd.html
HSL4263
Van Way CW 3rd.
The great rofecoxib feeding frenzy.
JPEN J Parenter Enteral Nutr 2005 Mar-Apr 01;29(2):136-8
http://jpen.aspenjournals.org/cgi/content/full/29/2/136
HSL6578
Schommer JC.
Direct-to-Consumer advertising for prescription drugs.
Minn Med 2005 Mar 01;88(3):32-3,
HSL5391
Arellano FM.
The withdrawal of rofecoxib.
Pharmacoepidemiol Drug Saf 2005 Mar;14(3):213-7
Link to source with long URL
HSL5396
Shatin D, Gardner JS, Stergachis A, Blough D, Graham D.
Impact of mailed warning to prescribers on the co-prescription of tramadol and antidepressants.
Pharmacoepidemiol Drug Saf 2005 Mar;14(3):149-54
Link to source with long URL
HSL371
Mansfield PR, Vitry AI, Wright JM.
Withdraw all COX-2-selective drugs.
Med J Aust 2005 Feb 21;182(4):197
Link to source with long URL
HSL4264
Neuhaus J.
[Quality requirements for investigational medicinal products. The state authorities' point of view]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2005 Feb 01;48(2):189-95
Link to source with long URL
HSL5244
Halpern GM.
COX-2 inhibitors: a story of greed, deception and death.
Inflammopharmacology 2005;13(4):419-25
Link to source with long URL
HSL5326
Stiles GM.
Wyeth responds to criticism.
Md Med 2005 Aut;6(4):5,
HSL5965
Jureidini JN, Tonkin A.
Suicide and antidepressants in children (editorial)
Australian Prescriber 2005;28:110-1
http://www.australianprescriber.com/magazine/28/5/110/1/
HSL6132
Mansfield PR, Raven MK, Jureidini JN.
Depressed youth, suicidality and antidepressants
MJA 2005;183(5):275-276
http://www.mja.com.au/public/issues/183_05_050905/letters_050905_fm-1.html
HSL6345
Seamon MJ, Clauson KA.
Ephedra: yesterday, DSHEA, and tomorrow--a ten year perspective on the Dietary Supplement Health and Education Act of 1994.
J Herb Pharmacother 2005;5(3):67-86
HSL6407
Lambert BL, Lin SJ, Tan H.
Designing safe drug names.
Drug Saf 2005;28(6):495-512
HSL6017
Mansfield PR, Jureidini JN, Parry P.
The belief that fluoxetine is effective for depressed children persists but is unjustified
BMJ 2004 Dec 31;330
http://bmj.bmjjournals.com/cgi/eletters/330/7481/7
HSL488
Jureidini J, Tonkin A, Mansfield PR.
TADS study raises concerns.
BMJ 2004 Dec 4;329(7478):1343-4
http://bmj.bmjjournals.com/cgi/content/full/329/7478/1343-d
HSL5394
Turner EH.
A taxpayer-funded clinical trials registry and results database.
PLoS Med 2004 Dec;1(3):e60
Link to source with long URL
HSL5823
Langton PE, Hankey GJ, Eikelboom JW.
Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions: we need processes in place to follow up suspicions about serious adverse events.
Med J Aust 2004 Nov 15;181(10):524-5
http://www.mja.com.au/public/issues/181_10_151104/lan10728_fm.html
HSL416
Allen K, Mansfield P.
Changing attitudes to 'the change'.
Aust Fam Physician 2004 Nov;33(11):939-40
http://www.racgp.org.au/document.asp?id=15004
HSL6019
Mansfield PR.
Reply to Stephen Black and Nicholas DeMartinis
2004 Oct 15;329
http://bmj.bmjjournals.com/cgi/eletters/329/7468/748
HSL6020
Mansfield PR, Tonkin AL, Jureidini JN.
Antidepressants do less good than harm for children and adolescents
BMJ 2004 Oct 8;329
http://bmj.bmjjournals.com/cgi/eletters/329/7470/809
HSL2091
Andrews E, Dombeck M.
The role of scientific evidence of risks and benefits in determining risk management policies for medications.
Pharmacoepidemiol Drug Saf 2004 Sep;13(9):599-608
http://www3.interscience.wiley.com/cgi-bin/abstract/105560406/ABSTRACT
HSL5473
Phillips GC.
Medicolegal issues and ergogenic aids: trade, tragedy, and public safety, the example of ephedra and the Dietary Supplement Health and Education Act.
Curr Sports Med Rep 2004 Aug 01;3(4):224-8
HSL5881
Kaufman R.
The Neurontin Controversy: The Saga of Off-Label Drug Regulation Continues
Legal Electronic Document Archive: Harvard Law School 2004 Apr 1
http://leda.law.harvard.edu/leda/data/638/Kaufman.html
HSL2087
Berman A.
Reducing medication errors through naming, labeling, and packaging.
J Med Syst 2004 Feb;28(1):9-29
HSL2782
Goldman SA.
Communication of medical product risk: how effective is effective enough?
Drug Saf 2004;27(8):519-34
HSL1427
Katz A.
Observations and advertising: controversies in the prescribing of hormone replacement therapy
Health Care Women Int 2003 Dec;24(10):927-39
HSL2514
Dowden JS.
Coax, COX and cola.
Med J Aust 2003 Oct 20;179(8):397-8
http://www.mja.com.au/public/issues/179_08_201003/dow10457_fm-2.html
HSL2228
Richards D.
Problems and perils of prescription medicines.
Expert Opin Drug Saf 2003 Sep;2(5):509-11
Link to source with long URL
HSL1434
Groves KE, Sketris I, Tett SE.
Prescription drug samples--does this marketing strategy counteract policies for quality use of medicines?
J Clin Pharm Ther 2003 Aug;28(4):259-71
Link to source with long URL
HSL5438
Kabra SG.
Unsafe abortions and experimental excesses.
Issues Med Ethics 2003 Jul-Sep 01;11(3):79-80
HSL5882
Kaushal R, Shojania KG, Bates DW.
Effects of computerized physician order entry and clinical decision support systems on medication safety: a systematic review.
Arch Intern Med 2003 Jun 23;163(12):1409-16
http://archinte.ama-assn.org/cgi/content/full/163/12/1409
HSL1661
Jureidini J, Tonkin A.
Paroxetine in major depression.
J Am Acad Child Adolesc Psychiatry 2003 May;42(5):514
Link to source with long URL
HSL1467
Bond C, Hannaford P.
Issues related to monitoring the safety of over-the-counter (OTC) medicines.
Drug Saf 2003;26(15):1065-74
HSL2250
Vacheron-Trystram MN, Cheref S, Gauillard J, Plas J.
[A case report of mania precipitated by use of DHEA].
Encephale. 2002 Nov-Dec 28;6:563-6
Link to source with long URL
HSL2448
Fugh-Berman A, Pearson C.
The overselling of hormone replacement therapy.
Pharmacotherapy 2002 Sep;22(9):1205-8
HSL2439
Sackett DL.
The arrogance of preventive medicine.
CMAJ 2002 Aug 20;167(4):363-4
http://www.cmaj.ca/cgi/content/full/167/4/363
HSL2903
Berkowitz BA, Sachs G.
Life Cycle of A Block Buster Drug: Discovery and Development of Omeprazole (PrilosecTM)
Mol Interv 2002 Feb;2(1):6-11
Link to source with long URL
HSL2458
Shakir SA, Layton D.
Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria.
Drug Saf 2002;25(6):467-71
Nil
HSL5069
Kamm MA.
Pharmacological treatment of irritable bowel syndrome--from concept to sales.
Eur J Surg Suppl 2002(587):10-5
HSL2450
Hemminki E, McPherson K.
Value of drug-licensing documents in studying the effect of postmenopausal hormone therapy on cardiovascular disease.
Lancet 2000 Feb 12;355(9203):566-9
http://linkinghub.elsevier.com/retrieve/pii/S0140673699034327
HSL8517
Kizer JR, Kimmel SE.
Calcium channel blocker controversy: historical perspective and important lessons for future pharmacotherapies-International Society of Pharmacoepidemiology hot topic
Pharmacoepidemiology and Drug Safety 2000;9(1):25-36
HSL5927
Wood AJ, Stein CM, Woosley R.
Making medicines safer--the need for an independent drug safety board.
N Engl J Med 1998 Dec 17;339(25):1851-4
http://content.nejm.org/cgi/content/extract/339/25/1851
HSL6906
O-Brien KL.
Epidemic of pediatric deaths from acute renal failure caused by diethylene glycol poisoning
JAMA 1998;279:1180
HSL694
Menkes DB.
Hazardous drugs in developing countries.
BMJ 1997 Dec 13;315(7122):1557-8
http://bmj.bmjjournals.com/cgi/content/full/315/7122/1557
HSL2449
Hemminki E, McPherson K.
Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials.
BMJ 1997 Jul 19;315(7101):149-53
http://bmj.bmjjournals.com/cgi/content/full/315/7101/149
HSL672
Sukkari SR.
Weighing benefits and risks of drug to treat obesity.
CMAJ 1997 Mar 15;156(6):768-9
http://www.cmaj.ca/cgi/reprint/156/6/768
HSL711
Judge R.
Dangers of fluoxetine.
Lancet 1997 Mar 15;349(9054):809
HSL530
Lexchin J.
[Pharmaceutic regulation and inadequate drug prescription in Canada: the case of psychotropic drugs in the 1960s and early 1970s]
Sante Ment Que. 1997 Spring;22(1):283-300
Nil
HSL736
Bourguignon RP.
Dangers of fluoxetine.
Lancet 1997 Jan 18;349(9046):214
HSL710
Lal A, Moharana AK, Srivastava S.
Comparative evaluation of drug advertisements in Indian, British and American medical journals.
J Indian Med Assoc 1997 Jan;95(1):19-20
HSL691
Ollila E, Hemminki E.
Does licensing of drugs in industrialized countries guarantee drug quality and safety for Third World countries?
International Journal of Health Services 1997;27:309-328
Nil
HSL1712
Brodie MJ, Pellock JM.
Taming the brain storms: felbamate updated.
Lancet 1995 Oct 7;346(8980):918-9
HSL6280
Bell TR.
Bromocriptine and drug information
Lancet 1994;343:297
HSL6255
Re: the promotion of Septrin (co-trimoxazole)
1993 Oct
HSL5704
Merikangas JR.
Changing over-the-counter drugs while retaining the brand name.
Ann Intern Med 1993 Jun 15;118(12):988
http://www.annals.org/cgi/content/full/118/12/988
HSL5549
Drug promotion: stealth, wealth, and safety
The Lancet 1993;341:1507-1508
HSL5698
Makkonen K.
Problems in distribution of scientific knowledge: intrauterine contraceptive devices and drug catalogs.
Int J Health Serv 1993;23(1):173-83
HSL4486
Re: the promotion of DPT-P vaccine
1989 Oct
HSL4480
Re: the promotion of tetracycline syrups for children
1989 Jun
HSL4464
Re: the promotion of ketoconazole
1989 Feb
HSL4117
Misuse of antidiarrhoeal medicines
Lancet 1989;2:995
HSL4111
Postmarketing surveillance - how should doctors get involved?
Drug and Therapeutics Bulletin 1988 Nov 14;26(3):89-91
HSL4108
Re: the promotion of erythromycin with bromhexine
1988 Nov
HSL4100
MaLAM letter follow up—Organon
MaLAM Newsletter 1988 Sep:1
HSL4069
Smith EL.
Drug promotion in the Third World.
Lancet 1988 Jul 23;2(8604):224
HSL4090
Re: the promotion of high dose oestradiol and progesterone and high dose oestradiol and testosterone
1988 May
HSL4082
Re: the promotion of penicillin/streptomycin combination
1988 Feb
HSL3987
Post-marketing surveillance by drug manufacturers
Lancet 1988;2:977
HSL3989
An unscrupulous advertisement
Lancet 1988;1:1098
HSL3990
Baldini R.
Nitroglycerin tolerance
New England Journal of Medicine 1988;318:120
HSL3993
Cohen EP.
Advertising of prescription drugs
New England Journal of Medicine 1988;319:314-315
HSL3996
Ferguson A.
Commercial pharmaceutical medicine and medicalization: a case study from El Salvador
1988
HSL4020
Masson A, Rubin PH.
Advertising of prescription drugs
New England Journal of Medicine 1988;319:314
HSL4030
Pearse WH.
Advertising of prescription drugs
New England Journal of Medicine 1988;319:314
HSL2722
Soumerai SB, Avorn J, Gortmaker S, Hawley S.
Effect of government and commercial warnings on reducing prescription misuse: the case of propoxyphene.
Am J Public Health 1987 Dec;77(12):1518-23
Link to source with long URL
HSL3979
Re: the promotion of trimethoprim/sulphamethoxazole/guaiphenesin/ammonium chloride
1987 Oct
HSL3975
Re: the promotion of flunarizine
1987 Sep
HSL3973
Organon and anabolic steroids
WEMOS pharma group 1987 Aug
HSL3918
Spitzer WO, Hutchinson T, Lane D.
Postmarketing management of drug use: toward rational public policy.
CMAJ 1987 May 15;136(10):1022-4
HSL3963
Piroxicam
1987 May:1-7
HSL3937
MLAM letter follow up—Pfizer
1987 Feb:2
HSL3938
MLAM letter follow up—Scanpharm
1987 Feb:2
HSL3883
Greenhalgh T.
Drug prescription and self-medication in India: an exploratory survey.
Soc Sci Med 1987;25(3):307-18
HSL3914
Singleton SW.
Promoting Retrovir
New England Journal of Medicine 1987;317:1160
HSL3930
Wolffers I.
Drug information and sale practices in some pharmacies of Colombo, Sri Lanka.
Soc Sci Med 1987;25(3):319-21
HSL3860
Re: the promotion of amidopyrine/phenylbutazone/prednisolone
1986 Dec
HSL3852
MLAM letter follow up—Pfizer
MLAM Newsletter 1986 Nov
HSL3853
Re: the promotion of arsenic/strychnine
1986 Nov
HSL3850
Re: the promotion of oral streptomycin/chloramphenicol combination
1986 Oct
HSL3846
Re: the promotion of amrinone
1986 Sep
HSL3847
Re: the promotion of furazolidone/kaolin/pectin
1986 Sep
HSL3841
Re: the promotion of piroxicam
1986 Aug
HSL3803
Mahood CB, Rothwell RP, Holford N.
Slow-release theophylline (THEO-24)
N Z Med J. 1986 Jan 22;99(794):21
HSL3808
McGovern I.
Advertising and benzodiazepines
Medical Journal of Australia 1986;145:179
HSL3750
Re: the promotion of anabolic steroids for children
1985 Nov 01
HSL3748
Re: the promotion of vitamins A & E
1985 Sep 01
HSL3722
Loshak D.
Anti-inflammatory drugs under fire.
Lancet 1985 Feb 16;1(8425):410
HSL3737
Re: the promotion of Lomotil
1985 Jan 01
HSL3661
Wolffers I.
Telling doctors in a developing country about phenylbutazone.
Lancet 1984 Jul 7;2(8393):44
HSL3681
Re: the promotion of ethylestrenol
1984 Jul 01
HSL3677
Re: the promotion of Lomotil
1984 May 01
HSL3673
Re: the promotion of dipyrone
1984 Apr 01
HSL3621
Berner MS.
‘Misleading’ drug ad
Canadian Family Physician 1984;30:271-272
HSL3650
Philbrook FA.
‘Misleading’ drug ad
Canadian Family Physician 1984;30:272, 274
HSL3608
Re: the promotion of products containing amidopyrine
1983 Nov
HSL3244
Knight JL, Baumgartner RP.
Quality control information—its availability from pharmaceutical manufacturers
Hospital Formulary Management 1974;9(9):35, 37, 40-42, 50
HSL2935
Lennard HL, Epstein LJ, Bernstein A, Ransom DC.
Hazards implicit in prescribing psychoactive drugs.
Science 1970 Jul 31;169(944):438-41